§ 01 Overview
Overview
Pfizer once-daily oral GLP-1R agonist. Discontinued June 2023 due to elevated transaminases across the program.
Program discontinued 26 June 2023.
§ 02 Mechanism
Mechanism of action
Lotiglipron was a non-peptide GLP-1R agonist designed for once-daily oral dosing. Pfizer ended development in 2023 after observing liver enzyme elevations across trials.
- 01Historical: clinical signal in obesity/T2D
§ 03 Dosing
Dosing protocol
Standard Protocol
- Route
- Oral
- Frequency
- Daily
§ 04 Evidence
Evidence & research
Program discontinued 26 June 2023.
FDA Status
Not FDA-approved. Development discontinued.
§ 06 News
In the news
2 articles from the last 12 months · updates hourly
Lilly Ends Two Mid-Stage Trials for Second Oral Obesity Asset - BioSpace
Lilly Ends Two Mid-Stage Trials for Second Oral Obesity Asset BioSpace
Pfizer's embattled obesity program loses another GLP-1 over poor data and strong competition - Fierce Biotech
Pfizer's embattled obesity program loses another GLP-1 over poor data and strong competition Fierce Biotech
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Transaminase elevation
Contraindications
None specified.
§ 10 Questions
Lotiglipron FAQ
- What is Lotiglipron?
- Pfizer once-daily oral GLP-1R agonist. Discontinued June 2023 due to elevated transaminases across the program. Lotiglipron was a non-peptide GLP-1R agonist designed for once-daily oral dosing. Pfizer ended development in 2023 after observing liver enzyme elevations across trials.
- What is Lotiglipron used for?
- Reported uses include historical: clinical signal in obesity/t2d. Evidence strength is rated Experimental — see the evidence section for detail.
- What are the side effects of Lotiglipron?
- Commonly reported side effects include transaminase elevation. This list is not exhaustive.
- Is Lotiglipron legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Not FDA-approved. Development discontinued..